Most mid-market hospital buyers approaching AI prior authorization for the first time are evaluating the wrong things. They're looking at vendor slide decks, feature lists, and marketing claims — when what they should be evaluating is whether the vendor's operational model maps to the actual compliance and staffing constraints their utilization management team operates under. This guide covers the four evaluation angles that separate a confident purchase from a costly vendor lock-in.
1. Speed as a Structural Differentiator — Not a Convenience Metric
The first thing a vendor will tell you is that their AI reduces turnaround time. The more important question is whether that speed is a structural capacity or a marketing claim. Under CMS-0057-F, 7-day standard and 72-hour expedited PA decision windows are compliance mandates — they are not aspirational targets. A vendor that can demonstrate 24-hour average turnaround under production volume is not offering a convenience feature; they are offering a compliance capability.
Speed matters for three reasons that go beyond operational convenience:
- Contract and network retention. Providers choosing where to send referrals factor PA turnaround into their network decisions. Slow PA turnaround is a documented driver of specialist network attrition — and specialist exits drive member churn.
- CMS compliance exposure. CMS-0057-F mandates specific decision windows. A vendor that cannot demonstrate consistent turnaround compliance during volume spikes is a compliance liability, not just an operational one.
- Star Rating and CAHPS impact. Turnaround time is an input to the CMS access-to-care composite score. Consistent speed translates into measurable Star Rating protection over reporting cycles.
When evaluating AI prior authorization vendors, ask for production turnaround benchmarks — not pilot phase numbers, not demo environment results. The benchmarks that matter are average, p95, and p99 turnaround time at the volume levels your UM team actually processes.
| Review Type | Manual Average | AI-Automated Average | CMS-0057-F Deadline |
|---|---|---|---|
| Standard (non-urgent) | 5–9 days | 18–36 hours | 7 calendar days |
| Expedited (urgent) | 48–72 hours | 4–12 hours | 72 hours |
| Automated approval routing | N/A (requires human review) | 2–6 hours | Counts toward deadline |
2. Pricing Model Transparency — What "Per-Case" Actually Costs at Scale
AI prior authorization vendors use three dominant pricing structures. Each maps to different organizational profiles and carries different long-term cost implications:
- Per-request pricing. A fixed fee per PA case processed. Predictable at low volume; scales linearly. Best for mid-market plans with stable, predictable PA volume — typically 50K–200K cases per year.
- Subscription + overage. A monthly base fee covering a defined case volume, with per-case charges above the threshold. Predictable baseline cost with upside flexibility. Best for plans with seasonal volume variation or planned membership growth.
- Outcome-based pricing. Fees tied to outcomes — approvals processed, denials avoided, appeal costs reduced. Aligns vendor incentives with buyer goals, but requires robust measurement agreements upfront. Best for larger mid-market plans with established UM metrics and a preference for risk-sharing arrangements.
For most mid-market hospital buyers, the subscription + overage model strikes the right balance between predictability and flexibility. Per-request pricing at high volume can exceed the total cost of a subscription arrangement within 6–9 months. Before signing a per-case contract, model your expected annual volume against the per-case rate and compare against the equivalent subscription floor.
| Pricing Model | Best Suited For | Mid-Market Self-Qualifier | Key Risk to Watch |
|---|---|---|---|
| Per-request | Plans with stable, predictable PA volume; 50K–200K cases/year | Regional hospital systems, small-to-mid MCOs | Linear cost scaling at high volume; no baseline predictability at enterprise scale |
| Subscription + overage | Plans with seasonal or growth-driven volume variation | Mid-size hospitals with variable census; plans anticipating membership changes | Overage charges at volume spike without clear cap mechanism |
| Outcome-based | Larger plans with established UM metrics; risk-sharing preference | Mid-size MCOs with advanced UM reporting; 200K+ cases/year with defined KPI baseline | Measurement disputes; outcome definitions that favor the vendor in edge cases |
3. Staffing Impact — What AI Actually Changes for Your UM Team
The honest answer to "what does AI deployment do to our UM team?" depends on your current workflow composition. If your team spends 60% of review time on documentation and routing — and only 40% on actual clinical decision-making — AI automation has a significant workflow restructuring effect. If your team is already running at high clinical decision-making density, the impact is more modest but still meaningful.
The evaluation question is not "will this reduce headcount?" — it is "what will your UM team spend their time doing after deployment?" The answer should be: more clinical reasoning, less administrative processing. That is the operational sustainability case for AI in utilization management.
Three staffing dynamics are worth evaluating explicitly with any vendor:
- Role redefinition. Reviewers move from primary document handlers to AI output confirmers. This is a meaningful shift in job function — it requires training, a revised performance management structure, and explicit onboarding on human-in-the-loop workflows. Vendors that treat this as a simple transition rather than a change management process will underdeliver on productivity outcomes.
- Workflow integration. AI prior authorization does not replace your PA system — it layers on top of it via API integration. The workflow transition requires your team to adopt a new interface for case routing, approval confirmation, and exception handling. Evaluate whether the vendor's interface integrates with your existing system or requires a parallel workflow.
- Productivity metrics. Establish baseline metrics before deployment: cases per reviewer per day, average turnaround time, denial rate by service category, appeal rate. These baselines let you measure actual productivity impact at 30-, 60-, and 90-day intervals rather than relying on the vendor's reported benchmarks.
| UM Team Function | Before AI Deployment | After AI Deployment | Productivity Impact |
|---|---|---|---|
| Case intake and routing | Manual data entry, eligibility verification, case creation | AI automated; reviewer confirms or flags exceptions | 60–70% time reduction on intake tasks |
| Clinical criteria matching | Manual guideline lookup; average 12–18 min per case | AI matched; reviewer validates and confirms | 70–80% time reduction; consistency improvement |
| Denial letter generation | Template selection, manual population, legal review | AI generated with criterion citation; reviewer approves | 50–60% time reduction; compliance quality improvement |
| Exception and complex case review | All cases in queue; highest-volume work area | AI filters straightforward cases; reviewer handles complex exceptions | Reviewer capacity freed for highest-acuity cases |
4. Clinical Criteria Coverage — The Question That Separates Vendors
Every vendor will claim "comprehensive clinical guideline coverage." What that means in practice varies significantly, and the variation matters for your compliance and audit exposure. Evaluate clinical criteria on four dimensions:
- Guideline library breadth. InterQual (MCG acquired by Hearst), MCG, ASAM, CMS Local Coverage Determinations (LCDs), and plan-specific proprietary criteria — most mid-market hospital PA programs use a primary library plus two or three supplementary sources. A vendor that supports only one primary library may require you to compromise on your existing guideline standard.
- Update frequency. Clinical guidelines are updated quarterly to annually depending on the library. A vendor that updates on a 12-month cycle may be applying outdated criteria to current cases — which creates both clinical quality and audit trail exposure. Ask for the vendor's update cadence and the last update date for each library they support.
- Customization capability. Plan-specific criteria — the rules your UM team applies that reflect your organization's clinical philosophy and payer contract requirements — are not in any published guideline library. A vendor that supports only uncustomized guideline application will leave gaps in your review process that your team has to manually close. Evaluate whether the platform supports custom criteria authoring, custom rules configuration, and plan-specific workflow branching.
- Audit trail for criteria applied. Every AI-assisted review should log the specific criterion node applied — not the guideline name, the specific criterion. CMS-0057-F audit trail requirements demand this level of specificity. A vendor that can produce a criterion citation in their system of record, at the case level, is a fundamentally different compliance capability than one that logs only the guideline category.
| Evaluation Criterion | Minimum Standard | Strong Performance | Red Flag |
|---|---|---|---|
| Guideline library support | InterQual or MCG as primary library | InterQual + MCG + ASAM + CMS LCDs with API-fed updates | Single library; no supplementary sources; manual update process |
| Update frequency | Annual update cycle | Quarterly updates with automated propagation to live system | Update cycle unknown or undocumented; no automated update mechanism |
| Custom criteria support | Plan-specific custom rules configurable by vendor | Self-service custom criteria authoring and version control in platform | Custom criteria not supported; all plans on identical criteria library |
| Audit trail logging | Guideline name logged per case | Specific criterion node (code + version + date) logged per case in queryable field | Free-text reviewer notes as only criterion record; no structured logging |
| Denial specificity | Denial letter cites guideline name and category | Denial letter cites exact criterion node and version used for decision | Generic denial language; no criterion citation in letter output |
Download the Evaluation Checklist
This guide covers the four angles most buyers evaluate last — and the ones that make the difference between a purchase decision you feel confident about and one you spend the next 18 months managing. The evaluation checklist below consolidates all four sections into a single scoring sheet your team can use to compare vendors side by side. It includes the pricing model self-qualifier, the staffing impact baseline, and the clinical criteria evaluation rubric — structured so you can complete it in a vendor demo and use it as the basis for a comparison conversation.
Frequently Asked Questions
Common questions that come up during mid-market hospital AI prior authorization evaluations:
| Question | Answer |
|---|---|
| What does the typical integration timeline look like for a mid-market hospital? | Most mid-market implementations run 8–12 weeks from contract signing to full-volume production. Weeks 1–2 cover API integration with the existing PA intake system — this is the phase with the most variation, depending on the age and documentation quality of your current PA platform. Weeks 3–6 cover criteria library configuration and custom rule authoring. Weeks 7–8 cover UM team training and human-in-the-loop workflow onboarding. Weeks 9–12 run parallel production: AI processing live volume alongside existing workflows, with your team confirming AI outputs and flagging exceptions. By week 12, most teams are running full volume with AI as the primary review layer. |
| How should mid-market hospitals approach pricing negotiation with AI prior authorization vendors? | Start with volume transparency. Most vendors price on case volume, and your actual annual volume is the primary lever in negotiations. If your historical PA volume data shows seasonality or planned growth, use that to negotiate a subscription structure with a defined overage cap rather than a pure per-case rate. Ask about outcome-based pricing components — a vendor confident in their denial rate reduction capability will often agree to a portion of fees tied to measured outcomes. For mid-market plans in the 75K–150K annual case range, multi-year contracts (2–3 years) with annual volume review clauses typically yield 15–25% better unit economics than annual contracts. |
| What does the staffing transition actually look like for a UM team adopting AI prior authorization? | The transition is workforce change management, not a reduction in force. The operational reality is that UM reviewers shift from handling all case types to handling exception and complex cases — the roughly 15–25% of cases that AI cannot automatically resolve. This is a role redefinition, not a role elimination. Teams that approach it as a reskilling investment — revised job descriptions, updated performance metrics, explicit training on human-in-the-loop confirmation workflows — tend to retain their best reviewers and report higher job satisfaction post-deployment. Teams that treat it as a cost-cutting measure typically experience higher turnover during the transition period, which erodes the productivity gains the AI was supposed to produce. |
| How do AI prior authorization vendors handle clinical criteria updates, and who absorbs the cost? | Update frequency and cost responsibility vary by vendor structure. Vendors that bundle guideline updates into subscription pricing are common for InterQual and MCG — these libraries publish quarterly updates, and the major AI platforms propagate them automatically to production environments at no additional cost. CMS LCD updates are more variable; some vendors maintain a live LCD feed via API, others update on a manual quarterly cycle. Plan-specific custom criteria authoring and updates are typically a shared responsibility — the vendor provides the configuration tooling, your clinical team maintains the criteria content. Ask any prospective vendor to document their update propagation timeline and confirm the update mechanism for each library they support before signing. |
| What security and HIPAA compliance posture should a mid-market hospital require from an AI prior authorization vendor? | Minimum requirements: BAA (Business Associate Agreement) with explicit HIPAA data handling provisions, annual third-party security audit (SOC 2 Type II is the standard), data encryption in transit and at rest, and defined data retention and deletion policies. Beyond the minimum, ask about PHI access controls — which individuals at the vendor organization have access to case data, under what authorization, and with what audit trail. AI vendors that use cloud-based model inference (rather than on-premise deployment) should be able to document exactly where their inference infrastructure runs and which data handling sub-processors are involved. For mid-market hospitals, vendors that resist providing their BAA template or security documentation before a verbal commitment are a signal to slow down the evaluation process. |